AB Science S.A. (AB.PA) has a MoatMap StockRank of 5/100 based on Quality (26/100), Value (34/100), and Momentum (22/100) factor scores. The current signal is STRONG SELL. AB Science is a French clinical-stage biotech with a history of regulatory setbacks for its lead compound masitinib. It does not meet our quality compounder or margin of safety requirements.
AB Science S.A. is a clinical-stage biopharmaceutical company focused on the research, development, and commercialization of novel targeted therapies, primarily its lead compound masitinib, for oncology, inflammatory, and neurodegenerative diseases. The company's competitive position relies on its proprietary tyrosine kinase inhibitor platform and extensive patent portfolio. It operates as a high-risk, high-reward niche biotechnology player in specialized medical fields.
| Price | $1.06 |
| Market Cap | $79M |
| P/E (Forward) | -6.64 |
| Price/Book | -2.26 |
| Return on Invested Capital | -203.6% |
| Gross Margin | 83.3% |
| Operating Margin | 510.9% |
| Revenue Growth | 28.7% |
AB Science S.A. operates in the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector (France).